Home › Funds › Pivotal bioVenture Partners Investment Advisor LLC › TRVI

Pivotal bioVenture Partners Investment Advisor LLC position in TRVI

TREVI THERAPEUTICS INC · Health Care

Pivotal bioVenture Partners Investment Advisor LLC reported holding 1,742,672 shares of TRVI (TREVI THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$25.0M, representing 10.17% of its reported portfolio and ranking #3 among its reported holdings. Pivotal bioVenture Partners Investment Advisor LLC has disclosed TRVI holdings in 6 of the last 6 reported quarters, going back to Q2 2025.

Latest position (Q3 2026)1.74M sh
Reported value held$24.96M
Portfolio Weight10.17%
First reportedQ2 2025
Last changeHold
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Pivotal bioVenture Partners Investment Advisor LLC's TRVI position evolved

Pivotal bioVenture Partners Investment Advisor LLC first disclosed a stake in TRVI in Q2 2025 at 1,146,110 shares (US$6.3M). The position peaked in Q2 2026 at 1,742,672 shares, worth US$32.5M. Across 6 filings, Pivotal bioVenture Partners Investment Advisor LLC increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 1,742,672 shares valued at US$25.0M.

Quarter by quarter

QuarterSharesValueChange
Q2 2025 1.15M $6.27M New
Q3 2025 1.26M $11.50M Add
Q4 2025 1.26M $15.73M Hold
Q1 2026 1.55M $18.54M Add
Q2 2026 1.74M $32.50M Add
Q3 2026 1.74M $24.96M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TRVI and 13F data

TRVI (TREVI THERAPEUTICS INC) is a Health Care company. 60 other funds we track also report a position in TRVI — the largest reported positions include NEA Management Company, LLC (US$246.6M), Frazier Life Sciences Management, L.P. (US$185.4M), Vivo Capital, LLC (US$60.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TRVI

All TRVI fund holders →

FAQ

How long has Pivotal bioVenture Partners Investment Advisor LLC held TRVI?

Pivotal bioVenture Partners Investment Advisor LLC has disclosed TRVI holdings in 6 of the last 6 reported quarters, going back to Q2 2025.

What is Pivotal bioVenture Partners Investment Advisor LLC's current position in TRVI?

As of Q3 2026, Pivotal bioVenture Partners Investment Advisor LLC holds 1.74M shares of TRVI (TREVI THERAPEUTICS INC), valued at $24.96M, representing 10.17% of its reported portfolio and ranking #3.

Has Pivotal bioVenture Partners Investment Advisor LLC been buying or selling TRVI?

In the latest 13F filing (Q3 2026), Pivotal bioVenture Partners Investment Advisor LLC held unchanged its position in TRVI. The position peaked in Q2 2026 at 1.74M shares.

Which other funds hold TRVI?

Other major institutional holders of TRVI include NEA Management Company, LLC, Frazier Life Sciences Management, L.P., Vivo Capital, LLC, among 60 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.